1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bravo At Last For GSK As MATINEE Succeeds In COPD

 
• By Andrew McConaghie

Nucala finally succeeds in a COPD Phase III study by narrowing its target patients, setting it up to compete in a huge new market to be led by Sanofi’s Dupixent.

New GSK sign

GSK’s severe eosinophilic asthma therapy, Nucala, has shown it can help cut exacerbations in chronic obstructive pulmonary disease (COPD) in a new Phase III study, making it a contender in an emerging multi-billion dollar field.

Nucala (mepolizumab), an interleukin-5 (IL-5) targeting antibody, had failed in two previous Phase III COPD studies, but tweaks to the targeted population in the MATINEE

Key Takeaways

  • Dupixent is set for a landmark COPD approval later this month, but GSK’s Nucala could now compete with it

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.